|
||
|
Press ReleaseAccuro Biologics Ltd announces multi-year service agreement with RocheCHICAGO, IL-April 9, 2006 --- Accuro Biologics Ltd, a privately held biotechnology services company, announces that it has entered into a multi-year service agreement with Roche. Under the agreement, Accuro Biologics will provide services within its core capabilities of antibody engineering, mammalian cell line engineering and T cell epitope evaluation. "We are delighted to be working with Roche so early in the development of our company and see this as an early endorsement of our operating plan and the technical capabilities within our group," said Graham Carter, Managing Director of Accuro Biologics. About Accuro Biologics LtdAccuro Biologics is a research services company serving the pharmaceutical, biotechnology and wider research community to provide access to advanced capabilities in protein and antibody engineering, mammalian cell line engineering and immunogenicity profiling. The company is UK-based and operates from its own fully equipped laboratories within the Aberdeen Science and Technology Park (Aberdeen, Scotland). For more information, please contact: Graham Carter Return to Press Releases |
||
Printer Friendly